

**Figure 1**

GATCAAACCTTCTTTCCATTCAGAGTCCTCTGATTCAGATTTAATGTTAACATTTTGGAAGACAGTATTCAGAAAAAATTTCC
TTAATAAAAAATACAACCTCAGATCCTTCAAATATGAACTGGTTGGGGAATCTCCATTTTTCAATATTATTTCTTCTTTGTTTC
TTGCTACGTATAATTATTAATATCCTGACTAGGTTGTGGTTGGAGGGTTATTACTTTTCATTTTACCATGCAGTCCAAATCTAAAC
TGCTTCTACTGATGGTTTACAGCATTCTGAGATAAGAATGGTACATCTAGAGAACATTTGCCAAAGGCCTAAGCACAGCAAAGGAA
AATAAACACAGAATATAATAAAATGAGATAATCTAGCTTAAACCTATAACTTCCTCTTTAGAACTCCCAACCACATTTGGATC

FIG. 2A

5' CAG AGA GGC TGT ATT TCA GTG CAG CCT GCC AGA CCT CTT CTG GAG GAA GAC TGG

 63 72 81 90 99 108
 ACA AAG GGG GTC ACA CAT TCC TTC CAT ACG GTT GAG CCT CTA CCT GCC TGG TGC

 117 126 135 144 153 162
 TGG TCA CAG TTC AGC TTC TTC ATG ATG GTG GAT CCC AAT GGC AAT GAA TCC AGT

 M M V D P N G N E S S
 171 180 189 198 207 216
 GCT ACA TAC TTC ATC CTA ATA GGC CTC CCT GGT TTA GAA GAG GCT CAG TTC TGG

 A T Y F I L I G L P G L E E A Q F W
 225 234 243 252 261 270
 TTG GCC TTC CCA TTG TGC TCC CTC TAC CTT ATT GCT GTG CTA GGT AAC TTG ACA

 L A F P L C S L Y L I A V L G N L T
 279 288 297 306 315 324
 ATC ATC TAC ATT GTG CGG ACT GAG CAC AGC CTG CAT GAG CCC ATG TAT ATA TTT

 I I Y I V R T E H S L H E P M Y I F
 333 342 351 360 369 378
 CTT TGC ATG CTT TCA GGC ATT GAC ATC CTC ATC TCC ACC TCA TCC ATG CCC AAA

 L C M L S G I D I L I S T S S M P K
 387 396 405 414 423 432
 ATG CTG GCC ATC TTC TGG TTC AAT TCC ACT ACC ATC CAG TTT GAT GCT TGT CTG

 M L A I F W F N S T T I Q F D A C L
 441 450 459 468 477 486
 CTA CAG ATT TTT GCC ATC CAC TCC TTA TCT GGC ATG GAA TCC ACA GTG CTG CTG

 L Q I F A I H S L S G M E S T V L L
 495 504 513 522 531 540
 GCC ATG GCT TTT GAC CGC TAT GTG GCC ATC TGT CAC CCA CTG CGC CAT GCC ACA

 A M A F D R Y V A I C H P L R H A T
 549 558 567 576 585 594
 GTA CTT ACG TTG CCT CGT GTC ACC AAA ATT GGT GTG GCT GCT GTG GTG CGG GGG

 V L T L P R V T K I G V A A V V R G
 603 612 621 630 639 648
 GCT GCA CTG ATG GCA CCC CTT CCT GTC TTC ATC AAG CAG CTG CCC TTC TGC CGC

 A A L M A P L P V F I K Q L P F C R

FIG. 2B

657				666				675				684				693				702			
TCC	AAT	ATC	CTT	TCC	CAT	TCC	TAC	TGC	CTA	CAC	CAA	GAT	GTC	ATG	AAG	CTG	GCC						
S	N	I	L	S	H	S	Y	C	L	H	Q	D	V	M	K	L	A						
711				720				729				738				747				756			
TGT	GAT	GAT	ATC	CGG	GTC	AAT	GTC	GTC	TAT	GGC	CTT	ATC	GTC	ATC	ATC	TCC	GCC						
C	D	D	I	R	V	N	V	V	Y	G	L	I	V	I	I	S	A						
765				774				783				792				801				810			
ATT	GGC	CTG	GAC	TCA	CTT	CTC	ATC	TCC	TTC	TCA	TAT	CTG	CTT	ATT	CTT	AAG	ACT						
I	G	L	D	S	L	L	I	S	F	S	Y	L	L	I	L	K	T						
819				828				837				846				855				864			
GTG	TTG	GGC	TTG	ACA	CGT	GAA	GCC	CAG	GCC	AAG	GCA	TTT	GGC	ACT	TGC	GTC	TCT						
V	L	G	L	T	R	E	A	Q	A	K	A	F	G	T	C	V	S						
873				882				891				900				909				918			
CAT	GTG	TGT	GCT	GTG	TTC	ATA	TTC	TAT	GTA	CCT	TTC	ATT	GGA	TTG	TCC	ATG	GTG						
H	V	C	A	V	F	I	F	Y	V	P	F	I	G	L	S	M	V						
927				936				945				954				963				972			
CAT	CGC	TTT	AGC	AAG	CGG	CGT	GAC	TCT	CCG	CTG	CCC	GTC	ATC	TTG	GCC	AAT	ATC						
H	R	F	S	K	R	R	D	S	P	L	P	V	I	L	A	N	I						
981				990				999				1008				1017				1026			
TAT	CTG	CTG	GTT	CCT	CCT	GTG	CTC	AAC	CCA	ATT	GTC	TAT	GGA	GTG	AAG	ACA	AAG						
Y	L	L	V	P	P	V	L	N	P	I	V	Y	G	V	K	T	K						
1035				1044				1053				1062				1071				1080			
GAG	ATT	CGA	CAG	CGC	ATC	CTT	CGA	CTT	TTC	CAT	GTG	GCC	ACA	CAC	GCT	TCA	GAG						
E	I	R	Q	R	I	L	R	L	F	H	V	A	T	H	A	S	E						
1089				1098				1107				1116				1125				1134			
CCC	TAG	GTG	TCA	GTG	ATC	AAA	CTT	CTT	TTC	CAT	TCA	GAG	TCC	TCT	GAT	TCA	GAT						
P	*																						
1143				1152				1161				1170				1179				1188			
TTT	AAT	GTT	AAC	ATT	TTG	GAA	GAC	AGT	ATT	CAG	AAA	AAA	AAT	TTC	CTT	AAT	AAA						
1197				1206				1215				1224				1233				1242			
AAA	TAC	AAC	TCA	GAT	CCT	TCA	AAT	ATG	AAA	CTG	GTT	GGG	GAA	TCT	CCA	TTT	TTT						
1251				1260				1269				1278				1287				1296			
CAA	TAT	TAT	TTT	CTT	CTT	TGT	TTT	CTT	GCT	ACA	TAT	AAT	TAT	TAA	TAC	CCT	GAC						
1305				1314				1323				1332				1341				1350			
TAG	GTT	GTG	GTT	GGA	GGG	TTA	TTA	CTT	TTC	ATT	TTA	CCA	TGC	AGT	CCA	AAT	CTA						



FIG. 2C

1359	1368	1377	1386	1395	1404
AAC TGC TTC	TAC TGA TGG	TTT ACA GCA	TTC TGA GAT	AAG AAT GGT	ACA TCT AGA
1413	1422	1431	1440	1449	1458
GAA CAT TTG	CCA AAG GCC	TAA GCA CGG	CAA AGG AAA	ATA AAC ACA	GAA TAT AAT
1467	1476	1485	1494	1503	1512
AAA ATG AGA	TAA TCT AGC	TTA AAA CTA	TAA CTT CCT	CTT CAG AAC	TCC CAA CCA
1521	1530	1539	1548	1557	1566
CAT TGG ATC	TCA GAA AAA	TGC TGT CTT	CAA AAT GAC	TTC TAC AGA	GAA GAA ATA
1575	1584	1593	1602	1611	1620
ATT TTT CCT	CTG GAC ACT	AGC ACT TAA	GGG GAA GAT	TGG AAG TAA	AGC CTT GAA
1629	1638	1647	1656	1665	1674
AAG AGT ACA	TTT ACC TAC	GTT AAT GAA	AGT TGA CAC	ACT GTT CTG	AGA GTT TTC
1683	1692	1701	1710	1719	1728
ACA GCA TAT	GGA CCC TGT	TTT TCC TAT	TTA ATT TTC	TTA TCA ACC	CTT TAA TTA
1737	1746	1755	1764	1773	1782
GGC AAA GAT	ATT ATT AGT	ACC CTC ATT	GTA GCC ATG	GGA AAA TTG	ATG TTC AGT
1791	1800	1809	1818	1827	1836
GGG GAT CAG	TGA ATT AAA	TGG GGT CAT	ACA AGT ATA	AAA ATT AAA	AAA AAA AAA
1845	1854	1863	1872	1881	1890
GAC TTC ATG	CCC AAT CTC	ATA TGA TGT	GGA AGA ACT	GTT AGA GAG	ACC AAC AGG
1899	1908	1917	1926	1935	1944
GTA GTG GGT	TAG AGA TTT	CCA GAG TCT	TAC ATT TTC	TAG AGG AGG	TAT TTA ATT
1953	1962	1971	1980	1989	1998
TCT TCT CAC	TCA TCC AGT	GTT GTA TTT	AGG AAT TTC	CTG GCA ACA	GAA CTC ATG
2007	2016	2025	2034	2043	2052
GCT TTA ATC	CCA CTA GCT	ATT GCT TAT	TGT CCT GGT	CCA ATT GCC	AAT TAC CTG
2061	2070	2079	2088	2097	2106
TGT CTT GGA	AGA AGT GAT	TTC TAG GTT	CAC CAT TAT	GGA AGA TTC	TTA TTC AGA
2115	2124	2133	2142	2151	2160
AAG TCT GCA	TAG GGC TTA	TAG CAA GTT	ATT TAT TTT	TAA AAG TTC	CAT AGG TGA
2169	2178	2187	2196	2205	2214
TTC TGA TAG	GCA GTG AGG	TTA GGG AGC	CAC CAG TTA	TGA TGG GAA	GTA TGG AAT
2223	2232	2241	2250	2259	2268
GGC AGG TCT	TGA AGA TAA	CAT TGG CCT	TTT GAG TGT	GAC TCG TAG	CTG GAA AGT
2277	2286	2295	2304	2313	2322
GAG GGA ATC	TTC AGG ACC	ATG CTT TAT	TTG GGG CTT	TGT GCA GTA	TGG AAC AGG
2331	2340	2349	2358	2367	2376
GAC TTT GAG	ACC AGG AAA	GCA ATC TGA	CTT AGG CAT	GGG AAT CAG	GCA TTT TTG




FIG. 2D

2385	2394	2403	2412	2421	2430
CTT CTG AGG GGC TAT TAC CAA GGG TTA ATA GGT TTC ATC TTC AAC AGG ATA TGA					
2439	2448	2457	2466	2475	2484
CAA CAG TGT TAA CCA AGA AAC TCA AAT TAC AAA TAC TAA AAC ATG TGA TCA TAT					
2493	2502	2511	2520	2529	2538
ATG TGG TAA GTT TCA TTT TCT TTT TCA ATC CTC AGG TTC CCT GAT ATG GAT TCC					
2547	2556	2565	2574	2583	2592
TAT AAC ATG CTT TCA TCC CCT TTT GTA ATG GAT ATC ATA TTT GGA AAT GCC TAT					
2601	2610	2619	2628	2637	2646
TTA ATA CTT GTA TTT GCT GCT GGA CTG TAA GCC CAT GAG GGC ACT GTT TAT TAT					
2655	2664	2673	2682	2691	2700
TGA ATG TCA TCT CTG TTC ATC ATT GAC TGC TCT TTG CTC ATC ATT GAA TCC CCC					
2709	2718	2727	2736	2745	2754
AGC AAA GTG CCT AGA ACA TAA TAG TGC TTA TGC TTG ACA CCG GTT ATT TTT CAT					
2763	2772	2781	2790	2799	2808
CAA ACC TGA TTC CTT CTG TCC TGA ACA CAT AGC CAG GCA ATT TTC CAG CCT TCT					
2817	2826	2835	2844	2853	2862
TTG AGT TGG GTA TTA TTA AAT TCT GGC CAT TAC TTC CAA TGT GAG TGG AAG TGA					
2871	2880	2889	2898	2907	2916
CAT GTG CAA TTT CTA TAC CTG GCT CAT AAA ACC CTC CCA TGT GCA GCC TTT CAT					
2925	2934	2943	2952	2961	2970
GTT GAC ATT AAA TGT GAC TTG GGA AGC TAT GTG TTA CAC AGA GTA AAT CAC CAG					
2979	2988	2997	3006	3015	3024
AAG CCT GGA TTT CTG AAA AAA CTG TGC AGA GCC AAA CCT CTG TCA TTT GCA ACT					
3033	3042	3051	3060	3069	3078
CCC ACT TGT ATT TGT ACG AGG CAG TTG GAT AAG TGA AAA ATA AAG TAC TAT TGT					
3087	3096	3105	3114	3123	3132
GTC AAG AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA					

AAA A 3'



Figure 3: Protein Sequence for 101P3A11.

MVDPNGNESSATYFILIGLPGLEEAQFWLAFPLCSLYLIAVLGNLTIIYIVRTEHSLHEPMYIFLCMLSGIDILI
STSSMPKMLAIFWFNSTTIQFDACLLQIFAIHSZSGMESTVLLAMAFDRYVAICHPLRHATVLTLPRTKIGV
AAVVRGAALMAPLPVFIKQLPFCRSNILSHSYCLHQDVMKLACDDIRVNVVYGLIVIISAIGLDSLLISFSYL
LILKTVLGLTREAQAKAFGTCVSHVCAVFIFYVPPFIGLSMVHFRFSKRRDSPLPVILANTYLLVPPVLNPIVYG
VKTKEIRQRILRLFHVATHASEP



Figure 4

Alignment of 101P3A11 (Sbjct) with mouse olfactory receptor S25 (Query)

Query: 34 GNYTVVTEFILLGLTDDITVSVILFVMFLIVYSVTLMGNLNIIIVLIRTSPQLHTPMYLF 93
 GN + T FIL+GL L +Y + ++GNL II ++RT LH PMY+FL
 Sbjct: 6 GNESSATYFILIGLPGLEEAQFWLAFPLCSLYLIAVLGNLTIIYIVRTEHSLHEPMYIFL 65

Query: 94 SHLAFLDIGYSSSVTPIMLRGFLRKGT FIPVAGCVAQLCIVVAFGTSESFLLASMAYDRY 153
 L+ +DI S+S P ML F T I C+ Q+ + + ES +L +MA+DRY
 Sbjct: 66 CMLSGIDILISTSSMPKMLAIFWFNSTTIQFDACLLQIFAIHSLSGMESTVLLAMAFDRY 125

Query: 154 VAICSPLLYSTQMSSTVCILLVGTSYLGGWVNAWIFTGCSLNL SFCGPNKINHFFCDYSP 213
 VAIC PL ++T ++ + + + G L FC N ++H +C +
 Sbjct: 126 VAICHPLRHATVLTLP RVTKIGVAAVVRGAALMAPLPVFIKQLPFCRSNLSH SYCLHQD 185


Query: 214 LLKLSCSHDFSFEVIPAISSGSIIVVTVFIIALSIVYILVSILKMRSTEGRQKAFSTCTS 273
 ++KL+C V I S I + +I+ SY+ IL ++L + + E + KAF TC S
 Sbjct: 186 VMKLACDDIRVNVVYGLIVIIISAIGLDSLLISFSYLLILKTVLGL-TREAQAKAFGTCVS 244

Query: 274 HLTAVTLFFGTITFIYVMPQSSYSTDQNK----VVSVFYTVVIPMLNPLIYSFRNKEVKE 329
 H+ AV +F+ + FI + +S ++ +++ Y +V P+LNP++Y + KE+++
 Sbjct: 245 HVCAVFIFY--VPFIGLSMVHRFSKR RDSPLPVILANIYLLVPPVLNPIVYGVKTKAIRQ 302

Query: 330 AMKKL 334
 + +L
 Sbjct: 303 RILRL 307



Figure 5:
101P3A11 Hydrophilicity profile
(Hopp T.P., Woods K.R., 1981. Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828)






Figure 6:
101P3A11 Hydropathicity Profile
(Kyte J., Doolittle R.F., 1982. J. Mol. Biol. 157:105-132)






Figure 7:
101P3A11 % Accessible Residues Profile
(Janin J., 1979. Nature 277:491-492)






Figure 8:
101P3A11 Average Flexibility Profile
(Bhaskaran R., Ponnuswamy P.K., 1988.
Int. J. Pept. Protein Res. 32:242-255)






Figure 9:
101P3A11 Beta-turn Profile
(Deleage, G., Roux B. 1987. Protein Engineering 1:289-294)




Figure 10A. Expression of 101P3A11 by RT-PCR

1 2 3 4 5 6 7 8 9




- VP1 (Kidney, Lung, Liver)
- VP2 (Pancreas, Colon, Stomach)
- Prostate xenograft Pool
- Prostate Cancer Pool
- Kidney Cancer Pool
- Colon Cancer Pool
- Breast Cancer Pool
- Metastasis Pool
- H2O

10004465, 052002




Figure 10B



100101469 . 052002



Figure 11. Expression of 101P3A11 in Human Patient Cancer Specimens



10µg total RNA/per lane from a pool of 3 tumors as follows:

Prostate Cancer Pool = gleason 6, 8, 9

Kidney Cancer Pool = grade 2, 2, 3

Colon Cancer Pool = stage II, III, IV

Breast Cancer Pool = grade 1, 2, 3

Metastasis Pool = colon to lung, colon to liver, ovary to fall. tube

NP = Normal Prostate



NB = Normal Bladder

NK = Normal Kidney

NC = Normal Colon



Figure 12A



Matched tumor/normal patient samples:


B = BPH
N = Normal
T = Tumor

10001469 .052002





Figure 12B and 12C






Figure 12D and 12E





Figure 13. Expression of 101P3A11 in Colon Cancer Patient Specimens



10001469 . 052002






Figure 14. Expression of 101P3A11 in Kidney Cancer Patient Specimens



10001769, 052002

Figure 15A-15C. Androgen Regulation of 101P3A11 in Tissue Culture Cells




- LAPC-9 cell line charcoal-stripped FBS, 14 hrs
- LAPC-9 cell line charcoal-stripped FBS, 14 hrs + mibolerone
- LAPC-9 cell line charcoal-stripped FBS, 24 hrs
- LAPC-9 cell line charcoal-stripped FBS, 24 hrs + mibolerone

10001469, 052402



Figure 16. Androgen Regulation of 101P3A11 *In Vivo*



10001469 - 052002





Figure 17. Expression and Detection of 101P3A11(159-202)-psecFc Fusion Protein



10001469-052002





Figure 18. Expression of 101P3A11 in 300.19 Cells



10001468 . 052002






Figure 19B-19C. Transmembrane prediction of 101P3A11

19B




19C



10004769 052003



Figure 20. Expression of 101P3A11 in NIH-3T3 Tumors



10001469 .052006






Figure 21: 101P3A11 Induces Tumor Formation of 3T3 Cells



•Injection of 10⁶ 3T3-neo, 3T3-Ras or 3T3-101P3A11 cells subcutaneously into SCID mice revealed that 6/6 3T3-Ras-injected mice formed tumors, 6/6 3T3-101P3A11-injected mice formed tumors, and 0/6 3T3-neo-injected mice formed tumors.

Figure 22: PTX Reduces the *in vivo* Growth of 3T3-101P3A11 Tumors



- Pertussis toxin inhibits the sub-cutaneous growth of 3T3-101P3A11 tumors in SCID mice.
- The inhibitory activity of pertussis toxin occurs in a dose dependent manner.




Figure 23: Alignment of 101P3A11-PHOR-1 with the rat GPCR RA1C (gi|3420759).

Identities = 179/299 (59%), Positives = 231/299 (76%), Gaps = 1/299 (0%)

PHOR: 14 FILIGLPGLEEAQFWLAFPLCSLYLIAVLGNLTIIYIVRTEHSLHEPMYIFLCMLSGIDI 73
 F+LIG+PGLEEA FW FPL S+Y +A+ GN +++IVRTE SLH PMY+FLCML+ ID+

RA1C: 11 FMLIGIPGLEEAHFWFGFPLLSMYAVALFGNCIVVFIVRTERSLHAPMYFLCMLAIDL 70

PHOR: 74 LISTSSMPKMLAIFWFNSTTIQFDACLLQIFAIHSLSGMESTVLLAMAFDRYVAICHPLR 133
 +STS+MPK+LA+FWF+S I FDACL Q+F IH+LS +EST+LLAMAFDRYVAICHPLR

RA1C: 71 ALSTSTMPKILALFWFDSREITFDACLAQMFFIHALSAIESTILLAMAFDRYVAICHPLR 130

PHOR: 134 HATVLTLPRTKIGVAAVVRGAALMAPLPVFIKQLPFCRSNILSHSYCLHQDVMKLCDD 193
 HA VL +IG+ A+VRG+ PLP+ IK+L FC SN+LSHSYC+HQDVMKLA D

RA1C: 131 HAAVLNNTVTQIGMVALVRGSLFFFPLPLLIKRLAFCHSNVLSHSYCVHQDVMKLAYTD 190

PHOR: 194 IRVNVVYGLIVIIISAIGLDSLLISFSYLLILKTVLGL-TREAQAKAFGTCVSHVCAVFIF 252
 NVVYGL I+ +G+D + IS SY LI++ VL L ++ +AKAFGTCVSH+ V F

RA1C: 191 TLPNVVYGLTAILVMGVDVMFISLSYFLIIRAVLQLPSKSERAKAFGTCVSHIGVVLAF 250

PHOR: 253 YVPFIGLSMVHRFSKRDSPLPVILANIYLLVPPVLNPIVYGVKTKAIRQIRLRLFHVA 311
 YVP IGLS+VHRF D + V++ ++YLL+PPV+NPI+YG KTK+IR R+L +F ++

RA1C: 251 YVPLIGLSVVHRFGNSLDPVHVLMGDVYLLLPVINPIIYGAKTKQIRTRVLAMFKIS 309

Figure 24: Alignment of 101P3A11-PHOR-1 with the human prostate specific GPCR. (gi|13540539)

Identities = 179/299 (59%), Positives = 233/299 (77%), Gaps = 1/299 (0%)

```

PHOR: 14  FILIGLPGLEEAQFWLAFPLCSLYLIAVLGNLTIIYIVRTEHSLHEPMYIFLCMLSGIDI 73
          F+LIG+PGLE+A FW+ FPL S+Y++A+ GN  +++IVRTE SLH PMY+FLCML+ ID+
GPCR: 11  FVLIGIPGLEKAHFWVGFPLLSMYVVMFGNCIVVFIVRTERS LHAPMYLFLCMLAAIDL 70

PHOR: 74  LISTSSMPKMLAIFWFNSTTIQFDACLLQIFAIHSLSGMESTVLLAMAFDRYVAICHPLR 133
          +STS+MPK+LA+FWF+S  I F+ACL Q+F IH+LS +EST+LLAMAFDRYVAICHPLR
GPCR: 71  ALSTSTMPKILALWFDSREISFEACLTQMFFIHALSAIESTILLAMAFDRYVAICHPLR 130

PHOR: 134 HATVLTLPRTKIGVAAVVRGAALMAPLPVFIKQLPFCSRNLSSHYSYCLHQDVMKLACDD 193
          HA VL      +IG+ AVVRG+      PLP+ IK+L FC SN+LSHSYC+HQDVMKLA D
GPCR: 131 HAAVLNNTVTAQIGIVAVVRGSLFFFFPLPLLIKRLAFCHSNVLSHSYCVHQDVMKLAYAD 190

PHOR: 194 IRVNVVYGLIIVIISAIGLDSLLISFSYLLILKTVLGL-TREAQAKAFGTCVSHVCAVFIF 252
          NVVYGL I+  +G+D + IS SY LI++TVL L ++  +AKAFGTCVSH+ V F
GPCR: 191 TLPNVVYGLTAILLVMGVDVMFISLSYFLIIRTVLQLPSKSERAKAFGTCVSHIGVVLA 250

PHOR: 253 YVPFIGLSMVHRFSKRRDSPLPVILANIYLLVPPVLNPIVYGVTKEIRQRILRLFHVA 311
          YVP IGLS+VHRF      + V++ +IYLL+PPV+NPI+YG KTK+IR R+L +F ++
GPCR: 251 YVPLIGLSVVHRFGNSLHPIVRVVMGDIYLLPPVINPIIYGAKTKQIRTRVLAMFKIS 309

```



Figure 25: Alignment with human olfactory receptor 5H12 (gi|14423836)

Identities = 163/304 (53%), Positives = 214/304 (69%), Gaps = 1/304 (0%)

```

PHOR: 7  NESSATYFILIGLPGLEEAQFWLAFPLCSLYLIAVLGNLTIIYIVRTEHSLHEPMYIFLC 66
      N +   +F+L G+PGLE +  WL+ PLC +Y +A+ GN  I+  VR E SLHEPMY FL
HOR5: 5  NVTHPAFFLLTGIPGLESSHWSLGGPLCVMYAVALGGNTVILQAVRVEPSLHEPMYIFLS 64

PHOR: 67  MLSGIDILISTSSMPKMLAIFWFNSTTIQFDACLLQIFAIHSLSGMESTVLLAMAFDRYV 126
      MLS D+ IS +++P +L F N+  I FDACL+Q+F IH  S MES +LLAM+FDRYV
HOR5: 65  MLSFSDVAISMATLPTVLRFTCLNARNITFDACLIQMFLIHFFSMMESGILLAMSFDRYV 124

PHOR: 127 AICHPLRHATVLTLPRTKIGVAAVVRGAALMAPLPVFIKQLPFCRSNILSHSYCLHQDV 186
      AIC PLR+ATVLT  +  +G+ A R      + PLP  IK+LP CRSN+LSHSYCLH D+
HOR5: 125 AICDPLRYATVLTTEVIAAMGLGAAARSFITLFPPLFIKRLPICRSNVLSHSYCLHPDM 184


PHOR: 187 MKLACDDIRNVVYGLIVIIISAIGLDSLLISFSYLLILKTVLGL-TREAQAKAFGTCVSH 245
      M+LAC DI +N +YGL V++S G+D  I SY+LIL++V+  +RE + KA  TCVSH
HOR5: 185 MRLACADISINSIYGLFVLVSTFGMDLFFIFLSYVLILRSVMATASREERLKALNTCVSH 244

PHOR: 246 VCAVFIFYVPFIGLSMVHRFSKRRDSPLPVILANIYLLVPPVLNPIVYGVTKEIRQRIL 305
      + AV  FYVP IG+S VHRF K      + V+++N+YL VPPVLNP++Y  KTKEIR+ I
HOR5: 245 ILAVLAFYVPMIGVSTVHRFGKHVPCYIHLMSNVYLFVPPVLNPLIYSAKTKEIRRAIF 304


PHOR: 306 RLFH 309
      R+FH
HOR5: 305 RMFH 308

```


Figure 26: 101P3A11 Modulated Tyrosine Phosphorylation in NIH-3T3 Cells




- 101P3A11 mediated the de-phosphorylation of proteins at 200, 120-140, 85-90 and 55 kDa
- 101P3A11 induced the phsophorylation of proteins at 80 and 29 kDa in NIH-3T3 cells.



10001469.052004

Figures 27A-27B: ERK Phosphorylation by PCR Ligands in 101P3A11 Expressing Cells




•FBS, lipophosphatidic acid, gastrin releasing peptide, leukotriene and platelet activating factor induced the phosphorylation of ERK in 101P3A11 expressing cells.

10001469 05002




Figure 28: Inhibition of 101P3A11-Mediated ERK Activation by PD98059



•ERK phosphorylation was inhibited by a MEK specific(PD98059) but not a p38 specific (SB203580) inhibitor in PC3-101P3A11 cells.



Figure 29: Enhanced ERK Phosphorylation in Sodium Orthovanadate Treated PC3-101P3A11 Cells



•Sodium orthovanadate induced increased ERK phosphorylation in PC3-101P3A11 cells relative to PC3-neo cells.

1000450 69410001





Figure 30: Inhibition of 101P3A11-Mediated ERK Phosphorylation
by AG1517



- The EGFR inhibitor, AG1517, inhibits EGF-mediated ERK phosphorylation in control and 101P3A11 expressing PC3 cells.
- AG1517 partially inhibits 101P3A11 mediated ERK phosphorylation in PC3 cells.





Figure 31A-31B: Activation of p38 in PC3-101P3A11 Cells



•Expression of 101P3A11 mediates p38 phosphorylation in cells treated with 10% FBS.

10001469, 052002



Figure 32: 101P3A11 Induced Accumulation of cAMP in PC3 Cells

Fold change in [cAMP]			
	PC3-Neo PC3-PHOR		
0.1%FBS	-PTX	1	4.302
	+PTX	1.403	2.577
10%FBS	-PTX	2.738	6.978
	+PTX	2.163	2.752

Fold Change in cAMP accumulation was calculated relative to PC3-neo cells grown in 0.1%FBS

- Expression of 101P3A11 increased the accumulation of cAMP in cells treated with 0.1% and 10% FBS.
- FBS-induced cAMP accumulation in 101P3A11 cells was inhibited by pertussis toxin.

10004462, 052002





Figure 33: Pertussis Toxin Inhibits 101P3A11 Mediated ERK Phosphorylation



•Pertussis toxin inhibited FBS- mediated ERK phosphorylation in 101P3A11 expressing cells.

10004459, 052002






Figure 34: Pertussis Toxin Inhibited ERK Phosphorylation in PC3-101P3A11 Cells




- Pertussis toxin inhibited FBS- mediated ERK phosphorylation in 101P3A11 expressing cells.
- The inhibitory activity of pertussis toxin on ERK phosphorylation was more dramatic in FBS-treated than EGF or GRP-treated PC3-101P3A11 cells.

Figure 35: Inhibition of 101P3A11 Mediated Signaling by Suranim



- Control NIH 3T3 and 3T3-101P3A11 cells were grown in the presence of absence of G protein inhibitors suranim and NF449. Proliferation was analyzed by Alamar blue after 72 hours.
- Suranim and NF449 inhibited the proliferation of 101P3A11 expressing but not control cells.


Figures 36A-36B: 101P3A11 Mediated ERK Phosphorylation By
Conditioned Media



- Supernatants from PC3, PC3-101P3A11, PrEC and LAPC4² cells induce ERK phosphorylation in PC3 101P3A11 but not PC3 cells.
- Supernatants from 3T3 and 293T cells had little specific effect on ERK phosphorylation.




Figure 37: 101P3A11 Enhances The Proliferation of 3T3 Cells



- Control NIH 3T3 and 3T3-101P3A11 cells were grown in the presence of absence 0.5 or 10% FBS. Proliferation was analyzed by Alamar blue after 48 hours.
- Expression of 101P3A11 induced a 6 fold increase in the proliferation of 3T3 cells grown in 0.5% FBS.



Figure 38: Inhibition of 101P3A11 Mediated ERK Phosphorylation by 101P3A11 Specific Antibodies




- Expression of 101P3A11 induced ERK phosphorylation in 293T cells.
- Anti-101P3A11 pAb inhibited ERK Phosphorylation in 293T-101P3A11 cells.

1000046 052002

2000046 052002

Figure 39: Anti-101P3A11 Ab Mediated cAMP Accumulation in PC3-101P3A11 Cells



Treatment	Fold Increase in cAMP	
	PC3	PC3-PHOR
0.1% FBS	1 ± 0.42	5.73 ± 0.47
PTX 1ug/ml	0.74 ± 0.28	2.12 ± 0.09
anti-PHOR	0.97 ± 0.35	4.01 ± 0.64

- Control PC3 cells and cells expressing 101P3A11 were treated with anti-101P3A11 pAb for 2 min and evaluated for intracellular cAMP content.
- The assay was performed in duplicate.





Figure 40A-40F



Fig.41A Prostate Cancer, 800X




Fig.41B Bladder Cancer, 800X




Fig.41C Kidney Cancer, 800X




Fig.41D Colon Cancer, 800X




Fig.41E Lung Cancer, 800X




Fig.41F Breast Cancer, 800X




Figure 42






Figure 43



Neo

101P3A11

Ras

Cell Line	Colony number	
	Average	
3T3-neo	0.5	
3T3-101P3A11	686	
3T3-Ras	249	

10001469 - 052002

